Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

অনুরূপ উপাদানগুলি

• Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)
  অনুযায়ী: Yoon, Shinkyo, অন্যান্য
  প্রকাশিত: (2017)
• 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
  অনুযায়ী: Schuette, Wolfgang, অন্যান্য
  প্রকাশিত: (2017)
• Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
  অনুযায়ী: Shih, Jin-Yuan, অন্যান্য
  প্রকাশিত: (2020)
• Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
  অনুযায়ী: Lu, Shun, অন্যান্য
  প্রকাশিত: (2016)
• Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
  অনুযায়ী: Kang, Jin Hyoung, অন্যান্য
  প্রকাশিত: (2016)